It is of course necessary to confirm these results in consecutive studies with a prospective design and comprehensive collection of possibly confounding baseline characteristics, yet even with these constraints, the present results justify further investigation towards the applicability of HMGB1 and the HMGB1/sRAGE ratio as a diagnostic tool in ovarian cancer. This evidence concerns the gene HMGB1 and ovarian cancer.